The study aims to determine the efficacy, safety, and tolerability of psilocybin in treating MDD.
Medical research organisation Usona Institute has commenced a Phase III clinical trial to evaluate the potential of psilocybin as a therapeutic option for adults diagnosed with major depressive disorder (MDD).
This marks a significant advancement in the development of psilocybin for medical use.
The gold standard of business intelligence.
Find out more
Dubbed the uAspire trial, the randomised, double-blind, multicentre study aims to determine the efficacy, safety, and tolerability of psilocybin in treating MDD.
Approximately 240 adults aged 18 years and above who are experiencing a major depressive episode will be enrolled in the trial.
Participants will receive a 25mg dose of psilocybin, administered alongside psychosocial support.
The initial phase of the trial will span six weeks. Following this treatment period, participants will undergo a one-year follow-up to assess the durability of the treatment and its long-term safety.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
Usona Institute chief medical officer Dr Mike Davis said: “The initiation of the Phase III uAspire trial marks an important milestone in the clinical development of psilocybin as a potential new treatment for major depressive disorder.
“Following the robust safety and efficacy findings from our Phase II study PSIL201, the uAspire trial is designed to deepen our understanding of psilocybin’s treatment durability and long-term safety.
“To ensure broad applicability of the study findings, we are committed to the inclusion of adults from diverse backgrounds and treatment settings, including top academic institutions, clinical research sites, and VA medical centres across the country.”
In November 2019, the US Food and Drug Administration (FDA) granted breakthrough therapy designation for psilocybin to treat MDD.
The designation comes after the company began a Phase II clinical trial, PSIL201, with 80 participants at seven study centres around the US. In August 2021, Usona Institute commenced the construction of a ‘Global Center in Psychedelic Science’ at Fitchburg, Wisconsin, US.
This facility is intended to offer training and education across academic discovery, clinical research and best practices in developing models for future approved therapies.
Give your business an edge with our leading industry insights.
The gold standard of business intelligence.
Find out more
Give your business an edge with our leading industry insights.
Give your business an edge with our leading industry insights.
I consent to Verdict Media Limited collecting my details provided via this form in accordance with Privacy Policy
View all newsletters from across the GlobalData Media network.
Hard data and deep insights on clinical trials strategy & operations
Powered by 
© Verdict Media Limited 2024
Usona Institute begins Phase III trial of psilocybin for MDD – Clinical Trials Arena
